Ra Medical Systems (RMED) Reports In-Line Q3 EPS, Revenues Miss

Ra Medical Systems (NYSE: RMED) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $1.08 million.

Recent Operational Highlights

• Twelve subjects enrolled in the Company’s atherectomy pivotal clinical trial, for a total of 13 subjects enrolled to date
• Positive test results support the path to extend the shelf life of future DABRA catheters
• Next-generation DABRA catheter projects are advancing on or ahead of schedule with prototypes available for in vitro testing
• The quality improvement program initiated in late 2019 is substantially complete

“I’m encouraged by the progress we’ve made during the third quarter and in recent weeks, in particular with patient enrollment in our atherectomy pivotal trial and with improvements and enhancements to the DABRA catheter,” said Will McGuire, Ra Medical Systems CEO. “We are executing well on our engineering, clinical and quality initiatives, and I am confident that we will deliver on our milestones.”

For earnings history and earnings-related data on Ra Medical Systems (RMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M